SHERIDAN, WYOMING – July 25, 2025 – Roche has received CE Mark certification for its Elecsys® pTau181 blood test, marking a pivotal advancement in Alzheimer’s diagnostics by introducing the first IVDR-certified in-vitro diagnostic test to help rule out Alzheimer’s-associated amyloid pathology. Developed in collaboration with Eli Lilly and Company, the test is designed to help clinicians exclude Alzheimer’s disease as the cause of cognitive decline using a simple blood sample, significantly reducing the need for invasive confirmatory procedures like PET scans or CSF analysis.

Minimally Invasive Test Aims to Address Diagnostic Gaps

SHERIDAN, WYOMING – July 25, 2025 – Roche has received European Commission (EC) approval for Itovebi™ (inavolisib), a targeted therapy for adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer. The approval marks a significant milestone in the treatment of a subtype associated with poor prognosis and limited therapeutic options.

Regulatory milestone based on robust clinical evidence

The EC’s decision was driven by data from the pivotal phase III INAVO120 study, published in The New England Journal of Medicine in October 2024. The trial demonstrated that the Itovebi-based regimen—when used in combination with palbociclib (Ibrance®) and fulvestrant—more than doubled progression-free survival (15.0 months vs. 7.3 months; HR=0.43; p<0.001) compared with palbociclib and fulvestrant alone.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced a significant step in the modernization of its capital structure, as its Board of Directors proposes to exchange the company's non-voting equity securities ("Genussscheine") for newly issued participation certificates. The proposal, which will be submitted to shareholders for approval at the 2026 Annual General Meeting (AGM), aims to align Roche’s capital instruments with current Swiss corporate law and modern market practices.

The proposed participation certificates will carry a nominal value of CHF 0.001 each and be listed on the SIX Swiss Exchange, offering the same economic value and entitlements as the Genussscheine they replace. In tandem, Roche also plans to reduce the nominal value of its bearer shares from CHF 1.00 to CHF 0.001 per share. This will result in a cash repayment of CHF 0.999 per bearer share, totaling approximately CHF 106.6 million, contingent on shareholder approval.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced topline results from two pivotal clinical trials evaluating astegolimab for chronic obstructive pulmonary disease (COPD), highlighting a complex development path for the investigational monoclonal antibody. The phase IIb ALIENTO trial met its primary endpoint, while the phase III ARNASA trial did not, despite both showing numerical reductions in exacerbation rates.

Phase IIb ALIENTO Achieves Statistically Significant Reduction in Exacerbations

The ALIENTO study, which enrolled 1,301 patients, demonstrated a statistically significant 15.4% reduction in the annualised exacerbation rate (AER) over 52 weeks when astegolimab was administered every two weeks on top of standard COPD maintenance therapy. The patient population included both current and former smokers, regardless of blood eosinophil count, with a history of frequent exacerbations.

SHERIDAN, WYOMING – July 25, 2025 – Küppersbusch Hausgeräte GmbH will present a fully redesigned dishwasher product line during Küchenmeile 2025, marking a significant milestone in the company’s strategic product development roadmap. Hosted in the brand’s showroom at Gut Böckel, this major industry event underscores Küppersbusch’s ongoing commitment to design excellence, energy efficiency, and market-driven innovation.

Showcasing Innovation and Strategic Expansion

Under the guiding theme “Inspire 2025: Impulse. Innovation. Interaktion.”, Küppersbusch invites trade partners, planners, and kitchen specialists to engage directly with its brand environment and explore key innovations that will shape the upcoming kitchen season. The introduction of an entirely new dishwasher portfolio marks a pivotal moment in the company's expansion efforts.

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has reaffirmed its long-term strategic transformation during its virtual Annual General Meeting (AGM) for fiscal year 2024/2025, underscoring the company’s commitment to becoming a systems integrator in packaging and to expanding into new technology-driven markets.

With approximately 27.5 percent of HEIDELBERG's share capital represented, the Management Board presented a comprehensive overview of the company’s financial performance, strategic progress, and outlook through a live-streamed session for shareholders and stakeholder representatives.

Positioning HEIDELBERG for the Future

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has signed an agreement with the Polar Group to acquire the technology, brand rights, and intellectual property (IP) of the renowned postpress specialist Polar Mohr, marking a pivotal step in its expansion strategy for the packaging and label market. The acquisition will give HEIDELBERG exclusive global rights for sales, service, and marketing of Polar Mohr postpress products, further solidifying its position as a comprehensive systems integrator.

Strategic Growth through Consolidation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.

Leadership Shifts Focused on Strategic Growth

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.

Investor Call Scheduled for August 7

Following the earnings release, Globus Medical will host a teleconference with the investment community at 4:30 p.m. Eastern Time on the same day. The company offers multiple ways for stakeholders to join the event:

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation